论文部分内容阅读
目的：探讨５－ＨＴ２ａ受体基因Ｔ１０２Ｃ多态性与利培酮疗效之间的关系。方法：抽取５６例连续住院的精神分裂症患者作研究，给予利培酮≥２ｍｇ／ｄ治疗两个月，用ＰＡＮＳＳ量表评定利培酮疗效，用聚合酶链式反应（ＰＣＲ）扩增及限制性片段长度多态性（ＲＦＬＰｓ）技术测定研究对象的基因型和等位基因。结果：发现利培酮疗效与５－ＨＴ２ａ受体基因Ｔ１０２Ｃ多态性无关联。结论：５－ＨＴ２ａ受体基因Ｔ１０２Ｃ多态性在利培酮药理作用机制中可能不起重要作用
Objective: To investigate the relationship between 5-HT2a receptor gene T102C polymorphism and the efficacy of risperidone. Methods: Fifty-six consecutive hospitalized patients with schizophrenia were enrolled in this study. Risperidone ≥2 mg / d was administered for two months. The efficacy of risperidone was assessed by PANSS scale. The effect of risperidone was evaluated by polymerase chain reaction (PCR) Restriction fragment length polymorphism (RFLPs) technique was used to determine the genotypes and alleles of the subjects. Results: The efficacy of risperidone was found to be unrelated to the T102C polymorphism of 5-HT2a receptor gene. Conclusion: The T102C polymorphism of 5-HT2a receptor gene may not play an important role in the pharmacological mechanism of risperidone